NCT06402513View on ClinicalTrials.gov

A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

October 8, 2024

Study Completion Date

October 8, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

Ravagalimab

Subcutaneous Injection

Trial Locations (1)

60030

Acpru /Id# 265325, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY

NCT06402513 - A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe | Biotech Hunter | Biotech Hunter